|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
81.33(B) |
Last
Volume: |
9,792,067 |
Avg
Vol: |
8,697,344 |
52
Week Range: |
$63.43 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,000 |
25,472 |
36,973 |
80,792 |
Total Sell Value |
$145,920 |
$2,022,270 |
$2,937,849 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
5 |
8 |
14 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dickinson Andrew D |
Chief Financial Officer |
|
2024-03-10 |
4 |
D |
$75.12 |
$338,416 |
D/D |
(4,505) |
134,983 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,732 |
139,488 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-03-10 |
4 |
D |
$75.12 |
$360,801 |
D/D |
(4,803) |
98,304 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,401 |
103,107 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-03-10 |
4 |
D |
$75.12 |
$342,472 |
D/D |
(4,559) |
118,432 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,844 |
122,991 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2024-03-10 |
4 |
D |
$75.12 |
$1,035,304 |
D/D |
(13,782) |
484,847 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,940 |
498,629 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-02-29 |
4 |
AS |
$72.74 |
$598,624 |
D/D |
(8,230) |
92,706 |
|
-10% |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-02-28 |
4 |
AS |
$73.18 |
$146,360 |
D/D |
(2,000) |
100,936 |
|
-11% |
|
Love Ted W |
Director |
|
2024-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
512 |
512 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2024-01-31 |
4 |
D |
$78.26 |
$1,832,067 |
D/D |
(23,410) |
129,436 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
74,961 |
152,846 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,646 |
11,728 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-01-31 |
4 |
D |
$78.26 |
$1,761,554 |
D/D |
(22,509) |
113,147 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
74,055 |
135,656 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2024-01-31 |
4 |
D |
$78.26 |
$6,208,757 |
D/D |
(79,335) |
468,689 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
230,747 |
548,024 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-01-31 |
4 |
D |
$78.26 |
$1,855,466 |
D/D |
(23,709) |
102,616 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
76,853 |
126,325 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2024-01-25 |
4 |
D |
$80.23 |
$15,565 |
D/D |
(194) |
7,082 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2024-01-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
514 |
7,276 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2024-01-16 |
4 |
AS |
$85.78 |
$428,900 |
D/D |
(5,000) |
101,534 |
|
-24% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-01-09 |
4 |
AS |
$85.23 |
$702,466 |
D/D |
(8,242) |
82,729 |
|
-21% |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-12-10 |
4 |
D |
$79.02 |
$94,350 |
D/D |
(1,194) |
106,534 |
|
- |
|
2511 Records found
|
|
Page 2 of 101 |
|
|